



Liver Transplantation for Cancer: The Future of Transplant Oncology

Guest Editor:

Prof. Dr. Tomoharu Yoshizumi

Department of Surgery and
Science, Graduate School of
Medical Sciences, Kyushu
University, 3-1-1, Maidashi,
Higashi-ku, Fukuoka City 812-
8582, Fukuoka, Japan

Deadline for manuscript
submissions:
closed (30 April 2024)

Message from the Guest Editor

Dear Colleagues,

Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a treatment that includes the underlying cirrhosis; theoretically, there is no better treatment. Many studies showed that selected patients with HCC can have improved outcomes after LT. Recently, other hepatobiliary malignancies, such as unresectable perihilar cholangiocarcinoma or liver metastasis for colorectal cancer, have been treated by LT with significant improved outcomes. The concept of such cancer treatment is defined as “transplant oncology”. On the other hand, there are some cautious views that LT for non-HCC malignancies including neuroendocrine tumors should be performed only in high-volume centers under strict selection criteria due to the current shortage of available organs. With this Special Issue, we aim to discuss the selection criteria, pre-LT treatment, appropriate immunosuppressive regimen, and strategies for the follow-up of LT for hepatobiliary malignancies to establish the concept of transplant oncology.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)